La vendita allo scoperto per Walker & Dunlop dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Walker & Dunlop. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Walker & Dunlop (NYSE:WD) Azioni, Report sulle vendite allo scoperto

Walker & Dunlop

Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company's products consist of first mortgage loans, second trust loans, supplemental financings, construction loans, mezzanine loans, and bridge/interim loans. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.

Walker & Dunlop Inc

Workday Inc

WORKDAY CL A ORD

WOODBROOK GROUP HLDGS by Woodbrook Group Holdings Inc.

Woodbrook Group Holdings Inc

Western Digital Corporation - Common Stock

Western Digital Corp

WILDCAT RESOURCES LTD by Wildcat Resources Ltd.

Wildcat resources Ltd

WESTERN DIGITAL ORD

Worlds Inc

IVZ S P ENRG ESG UCITS ETF ACC

UBS MSCI WO ESG LEAD USD A-ACC ETF

CSIFIE MWELB ETF

WD-40 Co

K9 Gold Corp

IVZ S P WLD FIN ESG UCITS ETF ACC

WOODLANDS FINL SVCS CO by Woodlands Financial Services Co.

Woodlands Financial Services Co

WOOD GROUP JOHN PLC by Wood Group (John) Plc.

John Wood Group PLC

WOOD GROUP JOHN UNSP/ADR by Wood Group (John) Plc.

Win Metals Ltd

WEDGEMOUNT RES CORP by Wedgemount Resources Corp.

Wedgemount Resources Corp

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Waterdrop Inc

WEEDHIRE INTL INC by WeedHire International, Inc.

WeedHire International Inc

Western Asset Diversified Income Fund Common Shares of Beneficial Interest

Western Asset Diversified Income Fund

SPDR S&P Global Dividend

PANACHE BEVERAGE INC by Panache Beverage Inc.

Panache Beverage Inc

DECENTRAL LIFE INC by Decentral Life, Inc.

Decentral Life Inc

WISDOM ED INTL HLDGS CO by Wisdom Ed Intl Hldgs Co Ltd.

MWESGLMVB BDL ETF

WisdomTree BioRevolution Fund

WISDOMTREE BIOREV UCITS ETF

WESDOME GOLD MINES LTD by Wesdome Gold Mines Ltd.

Wesdome Gold Mines Ltd

WAREHOUSES DE PAUW NV by WAREHOUSES DE PAUW NV

Warehouses De Pauw SA

Wangdiqiyuan International Holdings Ltd

Wanderport Corp

Woodside Energy Group Limited American Depositary Shares, each representing one Ordinary Share

Woodside Energy Group Ltd

MSCI WS CAP ETF

WORLD SCAN PROJ INC by WORLD SCAN PROJ INC

World Scan Project Inc

Defiance S&P 500 Enhanced Options & 0DTE Income ETF

IVZ S P WLD IT ESG UCITS ETF ACC

WedoTalk Inc

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.walkerdunlop.com%2F&amp;esheet=54147040&amp;newsitemid=20241104172634&amp;lan=en-US&amp;anchor=Walker+%26amp%3B+Dunlop%2C+Inc.&amp;index=1&amp;md5=8d30c32a3009b03207821d482e2cf43d">Walker &amp; Dunlop, Inc.</a> announced today that it facilitated a $110 million refinancing for an 18-property multifamily portfolio in New York City. Originally acquired in [2021] by a joint venture between Davean Holdings and Meadow Partners, the portfolio currently consists of 112 multifamily units and 29 commercial units located in some of the most desirable neighborhoods in the city including the East Village and Park Slope.

News

Financing

Walker & Dunlop Announces That It Facilitated A $110M Refinancing For An 18-property Multifamily Portfolio In New York City

Reported Earlier, Walker & Dunlop Announced That It Has Financed $137.29M For Luka On The Common, A 398-unit, 30-story Trophy Asset Located In The Heart Of Downtown Boston

Wedbush analyst Henry Coffey maintains Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) with a Neutral and raises the price target from $105 to $110.

Price Target

Analyst Ratings

Wedbush Maintains Neutral on Walker & Dunlop, Raises Price Target to $110

A significant insider transaction involving the exercise of company stock options was reported on August 27, by STEPHEN THEOBALD, EVP &amp; Chief Operating Officer at Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>), as per the latest SEC filing.
What Happened: THEOBALD, EVP &amp; Chief Operating Officer at Walker &amp; Dunlop, made a strategic move by exercising stock options for 13,870 shares of WD as detailed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001497770/000110465924093483//Archives/edgar/data/1497770/000110465924093483/0001104659-24-093483-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $1,177,701.
The Wednesday morning update indicates Walker &amp; Dunlop shares down by 1.03%, currently priced at $105.31. At this value, THEOBALD's 13,870 shares are worth $1,177,701.
<h3>Delving into Walker &amp; Dunlop's Background</h3>
Walker &amp; Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company's products consist of first mortgage loans, second trust loans, supplemental financings, construction loans, mezzanine loans, and bridge/interim loans. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
<h3>Unraveling the Financial Story of Walker &amp; Dunlop</h3>
Revenue Growth: Walker &amp; Dunlop's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -0.71%. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 44.24%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Walker &amp; Dunlop's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.67.
</li>
</ul>
Debt Management: Walker &amp; Dunlop's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.93.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 41.08 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.37 is above industry norms, reflecting an elevated valuation for Walker &amp; Dunlop's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 14.85, Walker &amp; Dunlop's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001497770">Check Out The Full List Of Walker &amp; Dunlop's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Insider Decision: STEPHEN THEOBALD Exercises Options At Walker & Dunlop For $1.18M

General

Walker & Dunlop Facilitated $128M In Financing For The Acquisition Of Nine Manhattan Properties, All Located Within A Two-block Stretch Of Manhattan's Vibrant East Village Neighborhood

Wedbush analyst Jay McCanless maintains Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) with a Neutral and raises the price target from $95 to $105.

Wedbush Maintains Neutral on Walker & Dunlop, Raises Price Target to $105

Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) reported quarterly earnings of $1.23 per share which beat the analyst consensus estimate of $0.79 by 55.7 percent. The company reported quarterly sales of $270.68 million which missed the analyst consensus estimate of $274.50 million by 1.39 percent. This is a 0.71 percent decrease over sales of $272.62 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Walker & Dunlop Q2 2024 Adj EPS $1.23 Beats $0.79 Estimate, Sales $270.68M Miss $274.50M Estimate

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) with a Market Perform and raises the price target from $105 to $112.

Keefe, Bruyette & Woods Maintains Market Perform on Walker & Dunlop, Raises Price Target to $112

Reported Earlier, Walker & Dunlop Arranges $167M Sale Of Millennium PQ, Second Largest Single-Asset Sale In California For 2024

The delinquency rate for U.S. office loans rose in June as vacancies grew due to the post-pandemic work-from-home trend and persistently high interest rates, according to a <a href="https://www.fitchratings.com/research/structured-finance/us-cmbs-delinquency-rate-ticks-higher-in-june-office-delinquencies-rise-further-12-07-2024">report </a>from Fitch Ratings.
The rate of delinquencies, or late payments, on loans behind commercial mortgage-backed securities (CMBS) rose to 2.45% in June from 2.42% in May, according to the report released on Friday. The volume of 30-day delinquencies increased to $1.92 billion from $1.86 billion over the same period.
The volume of 30-day delinquencies increased to $1.92 billion in June from $1.86 billion in May, increasing the 30-day delinquency rate to 0.35% in June from 0.34% in May. Office loans represented the largest share, accounting for 55% of 30-day delinquencies and totaling $1.05 billion, the report said.
Also Read: <a href="https://www.benzinga.com/real-estate/23/09/34368502/times-up-office-loans-its-payback-season">Time&#8217;s Up, Office Loans: It&#8217;s Payback Season</a>
The volume of loans that are at least 60 days delinquent reached $1.35 billion in June, up from $1.32 billion in May. Office loans accounted for $51%, or $692 million, of these new delinquencies, while retail made up 16%, or $214 million, and hotel represented 12%, or $162 million, of the delinquencies.
Three of the largest five new delinquencies were office loans, which accounted for 37% of total delinquency volume and 72% of office delinquencies, the report said.
The Illinois Center, secured by two adjoining 32-story office towers totaling 2.09 million square feet in the East Loop submarket of Chicago&#8217;s central business district, became 60 days delinquent on a $244 million loan in June 2024. 
The 1615 L Street loan of $134 million, secured by a 417,383-square-foot office building in downtown Washington D.C., was reported as a non-performing matured balloon loan in June 2024 that has been chronically delinquent after defaulting at its September 2023 maturity. 
The Zappettini Portfolio loan, valued at $120 million and secured by a portfolio of 10 office buildings in Mountain View, California, defaulted at maturity in June 2024, according to the report.
Price Action: Major commercial real estate lenders showed mixed performances on Friday.
CBRE Group, Inc. (NYSE: CBRE) gained 1.65% to close at $94.66, while Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) declined 0.47% to end the day at $99.68 and Cushman &amp; Wakefield plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWK#NYSE">CWK</a>) jumped 1.61% to $11.99.
Three exchange-traded funds that hold the most CBRE stock made modest gains on Friday. Invesco S&amp;P 500 Equal Weight Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPR#NYSE">RSPR</a>) gained 1.05%, while the Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) gained 0.73% and the iShares U.S. Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYR#NYSE">IYR</a>) edged up 0.84%.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/real-estate/23/11/35781692/loans-loom-large-u-s-office-building-owners-teeter-on-edge-of-default">Loans Loom Large: U.S. Office Building Owners Teeter On Edge Of Default</a></li>
</ul>
Photo: Shutterstock

ETFs

Real Estate

CBRE

iShares Trust Dow Jones US Real Estate Fund Index

RSPR

XLRE

Office Delinquencies Rise As Working From Home and Higher Rates Factor In

Walker & Dunlop Announced Today That It Arranged $148M In Loan Proceeds To Refinance The Victoria, A Multi Tower, 30-story Project Built Around Harlem's Heralded Victoria Theater Redevelopment

Reported Earlier, Walker & Dunlop Announced That It Successfully Arranged $29.6 Million In Federal Low-income Housing Tax Credit (lihtc) Equity For The Financing Of Canyon Creek East In Lenexa, Kansas

U.S. stocks were higher, with the Nasdaq Composite gaining over 250 points on Wednesday.
Shares of Casey&#8217;s General Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) rose sharply during Wednesday's session after the company reported better-than-expected quarterly financial results. Also, the company <a href="https://www.benzinga.com/news/earnings/24/06/39289435/why-caseys-general-stores-shares-are-surging-premarket-wednesday">increased its quarterly dividend</a>.
Sales of $3.60 billion exceeded the street view of $3.48 billion. EPS of $2.34 beat the consensus of $1.72, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Casey&#8217;s General Stores shares jumped 16.5% to $380.41 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) surged 27% to $36.56 after the company announced initial AOC 1020 data from the Phase 1/2 FORTITUDE trial demonstrating reductions of greater than 50% in DUX4 regulated genes, trends of functional improvement, and favorable safety and tolerability in people living with facioscapulohumeral muscular dystrophy.</li>
<li>Rentokil Initial plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>) jumped 15.5% to $31.10 following a report suggesting Trian has amassed a stake in the company.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) climbed 13.8% to $38.45. Brittain Resorts &amp; Hotels selected Affirm as exclusive pay over time partner to bring hotel guests a more flexible way to book accommodations.</li>
<li>Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) rose 12.8% to $47.12. Zillow Group Director Jay C Hoag acquired a total of 2,338,036 shares at an average price of $42.76.</li>
<li>Element Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) gained 12.6% to $26.72 as the company increased second quarter and full year guidance.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) jumped 11.2% to $34.43.</li>
<li>Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares jumped 10.7% to $137.08 after the company reported fourth-quarter financial results. Oracle posted weaker-than-expected earnings for its fiscal fourth quarter. The company also announced a partnership with Alphabet Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google Cloud.</li>
<li>Vornado Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) rose 10.3% to $26.18.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) gained 10.3% to $26.83.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) climbed 9.9% to $13.58.</li>
<li>Core &amp; Main, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) gained 9.2% to $51.51 as the company announced a $500 million share repurchase authorization.</li>
<li>SL Green Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) rose 9.1% to $57.38.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) gained 8.3% to $15.76.</li>
<li>Walker &amp; Dunlop, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) gained 8.1% to $99.70.</li>
<li>FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) gained 4% to $59.37.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose 3.7% to $214.73.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/06/39290293/how-to-earn-500-a-month-from-broadcom-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Broadcom Stock Ahead Of Q2 Earnings</a>

Intraday Update

Markets

Movers

AAPL

AFRM

CASY

ENVX

GOOG

GOOGL

ORCL

UPST

Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday

Wedbush analyst Henry Coffey reiterates Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) with a Neutral and maintains $95 price target.

Reiteration

Wedbush Reiterates Neutral on Walker & Dunlop, Maintains $95 Price Target

Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $0.52 by 128.85 percent. This is a 1.71 percent increase over earnings of $1.17 per share from the same period last year. The company reported quarterly sales of $228.059 million which missed the analyst consensus estimate of $251.817 million by 9.43 percent. This is a 4.48 percent decrease over sales of $238.746 million the same period last year.

Walker & Dunlop Q1 2024 Adj EPS $1.19 Beats $0.52 Estimate, Sales $228.059M Miss $251.817M Estimate

Walker &amp; Dunlop, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) shares are trading lower after&nbsp;Wedbush analyst&nbsp;Jay McCanless downgraded the stock to Neutral from Outperform and cut the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/WD/analyst-ratings" rel="noreferrer noopener">price target to $95 (from $130)</a>.
The analyst&#8217;s re-rating reflects the expectation that a higher for longer rate environment will again put pressure on transaction volumes this year.
The analyst says that the rate of volatility is showing no signs of easing and fears that the consistent rate of volatility seen thus far through 2024 has not helped to fix the ongoing negative leverage issue.
Although Walker &amp; Dunlop is one of the largest Agency multifamily lenders in the country, the analyst doesn&#8217;t expect the company to be the beneficiary of an expected 73% uptick in non-bank multifamily maturities this year.
Despite an expected increase in transaction and origination volumes in 2024, McCanless says that the higher rates could limit the amount of maturing loans that the company refinances.
Consequently, the analyst reduced EPS estimates to $3.40 (from $3.60) for 2024 and $4.30 (from $4.50) for 2025, owing to lower transaction volume assumptions.&nbsp;
Price Action: WD shares are down 1.60% at $91.15 on the last check Thursday.

Analyst Color

Equities

Downgrades

What's Going On With Walker & Dunlop Shares Today?

Shares of Fastenal Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fast#NASDAQ">FAST</a>) fell sharply during Thursday&rsquo;s session following worse-than-expected first-quarter financial results.
Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company&#39;s first-quarter EPS was 52 cents, missing the consensus of 53 cents.
Fastenal shares dipped 6.7% to $69.73 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Rallybio Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rlyb#NASDAQ">RLYB</a>) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson &amp; Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.</li>
<li>Rent the Runway, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rent#NASDAQ">RENT</a>) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance.</li>
<li>Eliem Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elym#NASDAQ">ELYM</a>) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement.</li>
<li>Akanda Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akan#NASDAQ">AKAN</a>) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.</li>
<li>Alpine Immune Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpn#NASDAQ">ALPN</a>) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.</li>
<li>Candel Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cadl#NASDAQ">CADL</a>) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.</li>
<li>Enliven Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elvn#NASDAQ">ELVN</a>) gained 26% to $24.97. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) rose 21.1% to $0.0923.</li>
<li>Globavend Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gvh#NASDAQ">GVH</a>) climbed 16.8% to $1.68.</li>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) gained 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) shares rose 15.3% to $1.9357.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) gained 14.6% to $15.91.</li>
<li>AnaptysBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anab#NASDAQ">ANAB</a>) climbed 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.</li>
<li>Verb Technology Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verb#NASDAQ">VERB</a>) gained 10.4% to $0.2010 after gaining 4% on Wednesday.</li>
<li>GigaCloud Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gct#NASDAQ">GCT</a>) rose 10.2% to $34.18.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrix#NASDAQ">NRIX</a>) gained 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.</li>
<li>StepStone Group LP (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/step#NASDAQ">STEP</a>) rose 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aptevo Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apvo#NASDAQ">APVO</a>) shares fell 58% to $1.01 after the company priced its $4.6 million public offering.</li>
<li>Enlivex Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/enlv#NASDAQ">ENLV</a>) fell 54.5% to $1.81. The company announced topline results of its Phase II trial evaluating Allocetra in sepsis.</li>
<li>AVITA Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcel#NASDAQ">RCEL</a>) fell 28.6% to $10.31 after the company announced an update to its expected commercial revenue for the first quarter of 2024. BTIG downgraded the stock from Buy to Neutral.</li>
<li>Aesthetic Medical International Holdings Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aih#NASDAQ">AIH</a>) fell 19% to $0.3723.</li>
<li>Globe Life Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gl#NYSE">GL</a>) fell 14.6% to $89.65.</li>
<li>The Lovesac Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/love#NASDAQ">LOVE</a>) shares fell 14.3% to $20.00 after the company reported worse-than-expected fourth-quarter results and issued first-quarter guidance.</li>
<li>Globe Life Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gl#NYSE">GL</a>) fell 13.7% to $90.56.</li>
<li>Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares declined 12.4% to $1.1601 after jumping around 32% on Wednesday.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) fell 12% to $0.7660 after declining 14% on Wednesday. Acorda Therapeutics recently commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.</li>
<li>CarMax, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kmx#NYSE">KMX</a>) fell 11.7% to $70.02 after the company reported lower-than-expected fourth-quarter earnings.</li>
<li>VBI Vaccines Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vbiv#NASDAQ">VBIV</a>) dipped 11.3% to $0.5641.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) fell 11.3% to $0.8680. On April 9, Wolfe Research analyst Scott Group initiated coverage on Nikola with a Peer Perform rating.</li>
<li>Marin Software Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrin#NASDAQ">MRIN</a>) declined 10.8% to $0.5798.</li>
<li>SolarBank Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/suun#NASDAQ">SUUN</a>) fell 9.3% to $5.29. SolarBank closed purchase of 3.15 MW solar project in New York from Storke Renewable.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) fell 9.1% to $2.29.</li>
<li>9F Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfu#NASDAQ">JFU</a>) fell 8.8% to $2.7046.</li>
<li>iCoreConnect Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icct#NASDAQ">ICCT</a>) shares fell 8.5% to $1.55 after jumping over 50% on Wednesday.</li>
<li>ClearOne, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clro#NASDAQ">CLRO</a>) declined 8.3% to $1.00. The company recently reported fourth-quarter financial results.</li>
<li>Nyxoah S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nyxh#NASDAQ">NYXH</a>) fell 7.3% to $9.83</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) fell 6.2% to $0.8164.</li>
<li>Walker &amp; Dunlop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wd#NYSE">WD</a>) fell 5.3% to $87.71 after Wedbush downgraded the stock from Outperform to Neutral and lowered its price target from $130 to $95.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38200890/top-3-health-care-stocks-which-could-rescue-your-portfolio-this-quarter"> Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter</a>

Penny Stocks

Small Cap

ACOR

AKAN

ALPN

ANAB

APVO

CADL

CLRO

ELVN

ELYM

ENLV

ESPR

FAST

GYRE

ICCT

JANX

LOVE

MRIN

NKLA

NRIX

NYXH

RCEL

RENT

RLYB

SLNA

SPRC

STEP

SUUN

VBIV

VERB

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

WIIM

Walker & Dunlop shares are trading lower after Wedbush downgraded the stock from Outperform to Neutral and lowered its price target from $130 to $95.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>JP Morgan raised the price target for F5, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ffiv#NASDAQ">FFIV</a>) from $197 to $205. JP Morgan analyst Samik Chatterjee maintained a Neutral rating. F5 shares fell 2.5% to close at $191.13 on Wednesday. <a href="https://www.benzinga.com/quote/FFIV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital boosted the price target for Gatos Silver, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gato#NYSE">GATO</a>) from $8 to $9. BMO Capital analyst Kevin O&#39;Halloran maintained a Market Perform rating. Gatos Silver shares gained 3.4% to close at $9.64 on Wednesday. <a href="https://www.benzinga.com/quote/GATO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut Walker &amp; Dunlop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wd#NYSE">WD</a>) price target from $130 to $95. Wedbush analyst Henry Coffey downgraded the stock from Outperform to Neutral. Walker &amp; Dunlop shares fell 4.3% to close at $92.64 on Wednesday. <a href="https://www.benzinga.com/quote/WD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for Apple Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) from $215 to $210. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares fell 1.1% to close at $167.78 on Wednesday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised Atlassian Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/team#NASDAQ">TEAM</a>) price target from $235 to $275. Barclays analyst Ryan Macwilliams upgraded the stock from Equal-Weight to Overweight. Atlassian shares rose 0.9% to close at $204.74 on Wednesday. <a href="https://www.benzinga.com/quote/TEAM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted STAAR Surgical Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/staa#NASDAQ">STAA</a>) price target from $45 to $53. Mizuho analyst Anthony Petrone maintained a Buy rating. STAAR Surgical shares fell 2.2% to close at $51.08 on Wednesday. <a href="https://www.benzinga.com/quote/STAA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for The Boeing Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>) from $210 to $190. B of A Securities analyst Ronald Epstein maintained a Neutral rating. Boeing shares fell 2% to close at $174.63 on Wednesday. <a href="https://www.benzinga.com/quote/BA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Berenberg raised Albemarle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alb#NYSE">ALB</a>) price target from $130 to $160. Berenberg analyst Andres Castanos Mollor upgraded the stock from Hold to Buy. Albemarle shares fell 1.2% to close at $127.65 on Wednesday. <a href="https://www.benzinga.com/quote/ALB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank raised Delta Air Lines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dal#NYSE">DAL</a>) price target from $50 to $60. Deutsche Bank analyst Michael Linenberg maintained a Buy rating. Delta Air shares fell 2.3% to close at $46.24 on Wednesday. <a href="https://www.benzinga.com/quote/DAL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) price target from $110 to $113. B of A Securities analyst Lorraine Hutchinson upgraded the stock from Neutral to Buy. NIKE shares fell 2.2% to close at $89.00 on Wednesday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/24/04/38198816/top-3-financial-stocks-that-are-ticking-portfolio-bombs"> Top 3 Financial Stocks That Are Ticking Portfolio Bombs </a>

FFIV

GATO

STAA

TEAM

Apple To $210? Here Are 10 Top Analyst Forecasts For Thursday

Wedbush analyst Henry Coffey downgrades Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) from Outperform to Neutral and lowers the price target from $130 to $95.

Wedbush Downgrades Walker & Dunlop to Neutral, Lowers Price Target to $95

In a report released yesterday, Jade Rahmani from KBW maintained a Hold rating on Walker & Dunlop (WD – Research Report), with a price target of $1...

KBW Remains a Hold on Walker & Dunlop (WD)

Analysts have been eager to weigh in on the Financial sector with new ratings on Heritage Global (HGBL – Research Report), Optimumbank Holdings (OP...

Analysts Offer Insights on Financial Companies: Heritage Global (HGBL), Optimumbank Holdings (OPHC) and Walker & Dunlop (WD)

Dividend Champion, Contender, And Challenger Highlights: Week Of August 18

Dividend Champion, Contender, And Challenger Highlights: Week Of September 1

How financial stocks may fare in a 'game of regulatory seats' under a Trump White House

Walker & Dunlop gets $137M financing for Boston project

SA Chart: Which sector will benefit the most from interest rate cuts?

Walker & Dunlop sources $110M for refinance of NYC multifamily portfolio

Walker & Dunlop announced that it facilitated a $110M refinancing for an 18-property multifamily portfolio in New York City. Originally acquired in...

Walker & Dunlop sources $110M to refinance NYC multifamily portfolio

Walker & Dunlop Q3 2024 Earnings Preview

AMAT

AMCR

AMGN

AMSF

ARCC

AROW

BOTJ

BWXT

BXSL

CBAN

CBOE

CBSH

CCBG

CCOI

CHCT

CHRW

CIVB

CLPR

CMCT

CNOB

COIN

CTAS

CTSH

EBMT

EBTC

EQIX

ESRT

EVRG

EWBC

Comments

Walker & Dunlop

Vendite allo scoperto

Walker & Dunlop (NYSE:WD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO